Bio-Rad Laboratories Inc (BIO) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.
Total Cash From Operating Activities Chart for Bio-Rad Laboratories Inc
Bio-Rad Laboratories Inc (BIO) operating cash flow for FY2025 was USD 532.2M, a 16.9% change from FY2024. Bio-Rad Laboratories Inc's operating cash flow grew from USD 9.8M in 1989 to USD 532.2M in 2025 (5330.6% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of -1.9%, 10-year CAGR of 11.1%, 20-year CAGR of 8.3%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $9.87B
- Implied Share Price
- $454.85
- Enterprise Value
- $9.81B
- Revenue (TTM)
- $2.59B
- EBITDA
- $441.00M
- Profit Margin
- 8.59%
- Trailing P/E
- 48.15
- Forward P/E
- 41.32
- Price/Book (MRQ)
- 1.41
- Price/Sales (TTM)
- 3.81
- EV/EBITDA
- 17.28
- EV/Revenue
- 3.79
- Dividend Yield
- —
- Book Value
- $268.30
- Free Cash Flow (FY2025)
- $374.60M
- Free Cash Flow Yield
- 3.80%
Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.